Bio-Techne, in partnership with Leica Biosystems, announced the automation of RNAscope™ COVID-19 probes on BOND RX, Leica's staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols.
"The Bio-Techne R&D team quickly developed COVID-19 specific probes when the genetic sequence of this virus was released," said Kim Kelderman, President, Diagnostics and Genomics Segment, Bio-Techne Corporation. "We believe RNAscope™ probes will enable researchers to gain a greater understanding of the pathogenesis of this disease. The availability of these probes on the automated Leica Biosystems platform will expediate important discoveries.”
The BOND RX is a flexible, open platform with the capability to run Bio-Techne RNAscope™ (duplex and multiplex) protocols, allowing for boundless innovation.
"We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation," said Melissa Aquino, President, Leica Biosystems. "The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment to support researchers in addressing the pandemic."
The RNAscope™ probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2.